CCM
KNSA icon

Consonance Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Consonance Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-2,374,392
Closed -$36.4M – 42
2020
Q3 		$36.4M Sell
2,374,392
-468,992
-16% -$8.8M 4.43% 9
2020
Q2 		$72.4M Buy
2,843,384
+602,605
+27% +$12.6M 4.34% 13
2020
Q1 		$34.7M Buy
+2,240,779
New +$35.1M 2.58% 16

Other funds holding KNSA

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Consonance Capital Management's KNSA Position: Q4 2020 in Review

Consonance Capital Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2020, closing a stake of 2,374,392 shares — an estimated $36.4M sold.

Consonance Capital Management first reported a position in KNSA in Q1 2020 and held it in 3 quarters. The position peaked at $72.4M in Q2 2020. 108 funds tracked by Wall St. Rank hold KNSA as of Q4 2020.

  • Consonance Capital Management reported no remaining Kiniksa Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Consonance Capital Management sold 2,374,392 Kiniksa Pharmaceuticals shares in Q4 2020, an estimated $36.4M.
  • Consonance Capital Management first reported a position in Kiniksa Pharmaceuticals in Q1 2020 and held it in 3 quarters.
  • Consonance Capital Management's Kiniksa Pharmaceuticals position peaked at $72.4M in Q2 2020.
  • 108 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2020.

Based on Consonance Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.